Early Treatment with New ALS Drug Combination Improved Survival

An open label extension shows additional benefit from a drug currently being tested for patients with Lou Gehrig’s disease.

3:45 PM

Author | Haley Otman

drawing of a brain in blue ink on lined paper with "lab note" branding on bottom right

Follow up data shows that not only did a new drug help slow the effects of amyotrophic lateral sclerosis, or ALS, on patients' day-to-day ability to function, but it may also keep patients alive longer when they start it early on in their disease course.

After taking part in a clinical trial for the drug known as AMX0035, 92% of the participants elected to use the drug in an open-label extension study. The people who had originally been randomized to take the drug had a 44% lower risk of death over a period up to three years compared to those who were originally randomized to placebo and then started the drug for the open-label extension.

"It is encouraging to see a drug that both slows the loss of function and lengthens the survival of ALS," says Stephen Goutman, M.D., director of the Michigan Medicine Pranger ALS Clinic and one of the researchers who led a trial site for the drug. AMX0035 is a combination of sodium phenylbutyrate and taurursodiol.

"It will be important to understand if these benefits extend to all persons with ALS or only those who begin treatment early in disease, as the main trial restricted entry to only those persons within the first 18 months of symptoms."

Goutman says the findings also demonstrate the value of including open label extensions in studies in order to better understand the longer-term outcomes of therapeutics.

"We are so grateful to all the persons with ALS who participated in this study here at Michigan Medicine and nationwide, and to Drs. Paganoni and Cudkowicz at Mass General for leading this study," Goutman adds.

The open label extension is ongoing, as are analyses of long-term functional and safety data. AMX0035 is not currently available to patients outside of this research setting. Pharmaceutical company Amylyx, which makes AMX0035, sponsored the research.

Paper cited: "Long-Term Survival of Participants in the CENTAUR Trial of Sodium Phenylbutyrate-Taurursodiol in ALS," Muscle & Nerve.

SEE ALSO: New Drug Combination May Slow Symptom Course Early on in ALS


More Articles About: Lab Notes Lou Gehrig's (ALS) Neurodegenerative Disorder Neurological (Brain) Conditions
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories drawing of brain in blue ink with yellow badge that says lab note in blue ink
Health Lab
Immune Cells Suggest Men and Women with ALS May Benefit from Different Treatment
Effective treatments for ALS have eluded scientists for decades. A new examination of the immune system shows the appeal of personalized medicine for future care.
drawing of a brain in blue ink on lined note paper
Health Lab
New Drug Combination May Slow Symptom Course Early on in ALS
Positive clinical trial points to possible additional option for patients with Lou Gehrig’s disease. A study investigator explains the excitement and the caution.
Patient lies in hospital bed after surgery with bandage on head, displays toys later after recovery
Health Lab
Lifechanging results for young woman after orange-sized brain tumor removed
Young woman thrives after surgery to remove a pilocytic astrocytoma tumor in her brain.
Three year old patient poses by Wonder Woman statue, wears costume
Health Lab
Three-year-old Wonder Woman making strides after customized spinal procedure
Three year old Wonder Woman fan thrives after customized minimally invasive selective dorsal rhizotomy to help symptoms of cerebral palsy and spastic diplegia
Illustration of neuron cell
Health Lab
Two genes linked to autism implicated in brain cell connectivity
A new study links two autism-associated genes together for the first time, potentially revealing a mechanism behind brain changes seen in people with autism.
brain image
Health Lab
Death rate higher than expected for patients with functional, nonepileptic seizures
The death rate for patients with functional, nonepileptic seizures is higher than expected, with a rate comparable to epilepsy and severe mental illness, a Michigan Medicine-led study finds.